SynVaccine is part of EU consortium for accelerating research & development for Advanced therapy medicinal products (ATMPs)
SynVaccine is a part of the ARDAT (Accelerating research & development for advanced therapies) distinguished consortium of the EU's Innovative Medicines Initiative. Among other things, ARDAT aims to deliver tools and knowledge that will allow researchers to study how treatments are metabolised, predict which treatments are likely to trigger a harmful immune response, and identify how best to deliver the therapy. ARDAT focuses on rare diseases caused by a single gene mutation. SynVaccine brings to ARDA its unique computational synthetic biology platform technology for viral engineering that enables an efficient design of AAV and transgene properties. Among others SynVaccine works on tools for designing aspects such as efficient expression of transgenes in target tissues, the efficient generation of AAV particles, as well as the tropism of AAV particle to the target tissue while minimizing the autoimmune response. Click the following link for more information on the ARDAT consortium https://www.imi.europa.eu/projects-results/project-factsheets/ardat
Check out our recent publication in Scientific Reports demonstrating SynVaccine's capabilities in Porcine circovirus
SynVaccine is a finalist in the Animal Health Innovation Europe 2020 Showcase Meeting
SynVaccine awarded Seal of Excellence from the European Commission
Nov 16, 2018 - The Seal of Excellence was received as part of SME instrument phase 2 submission
Israeli viral vaccines co SynVaccine raises $1.7m
01 Oct, 2017
SynVaccine was awarded the European Commission`s Horizon 2020 SME Instrument Phase 1 grant
28 June, 2017
Second prize award in the ITTN start-up competition
25 May, 2016
SynVaccine finalist at the Berlin Falling Walls Venture competition, one of 3 top science based start-ups of 2014
SynVaccine has been declared one of 3 top science based start-up of the Year (2014) by the a jury of 18 leaders from industry, investment and academics at the Falling Walls Venture competition.
More than 25 outstanding science based start-up companies from around the world presented their business ideas at the global forum Falling Walls Venture in Berlin. Nominated by leading international academic institutions and venture capitalists, each start-up had only five minutes to convince a distinguished jury of their business concepts. SynVaccine was chosen to be one of the three most promising start-ups of the year 2014.